Dr. Mutti on Current Role of Immunotherapy for Mesothelioma

Luciano Mutti, MD
Published: Wednesday, Feb 08, 2017



Luciano Mutti, MD, professor of Cancer Research, University of Salford Manchester, discusses the current role of immunotherapy for patients with mesothelioma.

The current role of immunotherapy for patients with mesothelioma is still unknown and should be better defined, Mutti explains. There is some biological data that is against the use of immunotherapy for mesothelioma.

The response rate of immunotherapy is not particularly effective, but Mutti says it is particularly important to look at what the survival rate will be in the future for a patient treated with immunotherapy. Until these results are available, physicians must be cautious when using immunotherapy to treat patients with mesothelioma.
 


Luciano Mutti, MD, professor of Cancer Research, University of Salford Manchester, discusses the current role of immunotherapy for patients with mesothelioma.

The current role of immunotherapy for patients with mesothelioma is still unknown and should be better defined, Mutti explains. There is some biological data that is against the use of immunotherapy for mesothelioma.

The response rate of immunotherapy is not particularly effective, but Mutti says it is particularly important to look at what the survival rate will be in the future for a patient treated with immunotherapy. Until these results are available, physicians must be cautious when using immunotherapy to treat patients with mesothelioma.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x